EMA accepts Ferrer anti-lipid drug MAA for review
The MAA, submitted under the name ‘TESAMORELIN FERRER,’ is based on the positive results from two Phase 3 clinical trials, which enrolled more than 800 patients, and follows
Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.